Pfizer Inc. (PFE)'s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Pfizer Inc. stands fifth among them.

Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to drive growth through innovation, commercial execution, and operational efficiency. The company’s portfolio spans vaccines and treatments for a range of diseases, including its high-profile COVID-19 vaccine, Comirnaty.

A major recent development is the FDA approval of Pfizer Inc. (NYSE:PFE) and BioNTech’s updated COVID-19 vaccine, COMIRNATY LP.8.1. Targeting the SARS-CoV-2 sublineage LP.8.1, the vaccine is authorized for adults 65 and older, as well as high-risk individuals aged 5–64. Shipping began immediately to ensure broad access for the upcoming respiratory season, reflecting Pfizer’s commitment to timely public health responses.

Financially, Pfizer Inc. (NYSE:PFE) reported strong second-quarter 2025 results with $14.7 billion in revenue, up 10% year-over-year, driven by key products including Vyndaqel and COVID-19 therapies. The business raised its full-year adjusted earnings outlook to $2.90–$3.10 per share, supported by cost-cutting initiatives expected to save $7.2 billion by 2027, with $4.5 billion anticipated by year-end 2025 through efficiencies in research and manufacturing operations.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.